CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP
· Real-Time Price · USD
47.45
0.75 (1.61%)
At close: Jun 27, 2025, 3:59 PM
46.84
-1.29%
After-hours: Jun 27, 2025, 05:58 PM EDT
CRISPR Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|
| Collaboration Revenue Revenue | 35M | 370M | 436K |
| Collaboration Revenue Revenue Growth | -90.54% | +84762.39% | n/a |
| Grant Revenue | 2.31M | 1.21M | 762K |
| Grant Revenue Growth | +91.87% | +58.27% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 19.3M | 18.12M | 17.42M | 19.48M | 17.95M | 16.48M | 18.29M | 19.03M | 22.36M | 21.17M | 27M | 26.27M | 28.02M | 24.13M | 24.35M | 29.81M | 24.52M | 25.77M | 21.54M | 21.35M | 19.55M | 17.27M | 15.52M | 15.77M | 14.93M | 16.54M | 10.18M | 12.74M | 8.84M | 11.32M | 8.11M | 7.77M | 8.64M | 12.08M | 4.11M | 8.75M | 6.12M | 6.24M | 2.45M | 2.14M | 2.57M |
| Selling, General, and Administrative Revenue Growth | +6.47% | +4.05% | -10.58% | +8.51% | +8.94% | -9.91% | -3.89% | -14.88% | +5.63% | -21.60% | +2.77% | -6.24% | +16.14% | -0.92% | -18.30% | +21.57% | -4.85% | +19.62% | +0.87% | +9.22% | +13.20% | +11.29% | -1.58% | +5.62% | -9.75% | +62.57% | -20.14% | +44.19% | -21.96% | +39.58% | +4.43% | -10.11% | -28.47% | +194.18% | -53.07% | +43.08% | -1.97% | +154.34% | +14.68% | -16.84% | n/a |
| Research and Development Revenue | 72.48M | 77.31M | 82.16M | 75.32M | 71.34M | 95.14M | 90.7M | 101.56M | 99.94M | 103.56M | 116.62M | 123.22M | 118.25M | 134.47M | 105.32M | 108.28M | 90.56M | 82.36M | 71.01M | 59.38M | 54.19M | 48.76M | 57.25M | 39.53M | 33.82M | 28.8M | 39.82M | 25.63M | 19.52M | 20.03M | 17.84M | 17.12M | 14.8M | 15.57M | 12.05M | 8.6M | 6.01M | 6.17M | 3.75M | 1.49M | 1.16M |
| Research and Development Revenue Growth | -6.25% | -5.90% | +9.08% | +5.58% | -25.02% | +4.90% | -10.69% | +1.62% | -3.50% | -11.20% | -5.36% | +4.21% | -12.07% | +27.68% | -2.73% | +19.56% | +9.96% | +15.99% | +19.58% | +9.57% | +11.14% | -14.82% | +44.81% | +16.89% | +17.43% | -27.67% | +55.35% | +31.32% | -2.55% | +12.24% | +4.23% | +15.64% | -4.93% | +29.21% | +40.11% | +43.08% | -2.62% | +64.68% | +152.29% | +27.66% | n/a |